ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

A Year in Houston: DePinho Reflects on Plans, Conflicts, Controversies—and Lessons Learned

September 7, 2012

DOD funds $4.2 million gynecologic oncology research program at four institutions.

July 2, 2004

Texas Voters Approve $3 Billion In Bonds For Cancer Research.

November 9, 2007

Kimes: Centers Need New $$ Sources; Fox Chase, U.Pa Go Seperate Ways

October 12, 1990

NINDS Awards Grants For Brain Tumor Centers

December 11, 1992

White House Order Poses Difficulties For NIH Peer Review

April 2, 1993